Cargando…

The use of angiotensin II receptor blocker is associated with greater recovery of cardiac function than angiotensin‐converting enzyme inhibitor in dilated cardiomyopathy

AIMS: Angiotensin‐converting enzyme inhibitors (ACEis) or angiotensin II receptor blockers (ARBs) have been shown to be associated with recovery of cardiac function in patients with dilated cardiomyopathy (DCM). The aim of this study was to assess comparative effectiveness of ACEis vs. ARBs on recov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Enzan, Nobuyuki, Matsushima, Shouji, Ide, Tomomi, Tohyama, Takeshi, Funakoshi, Kouta, Higo, Taiki, Tsutsui, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934926/ https://www.ncbi.nlm.nih.gov/pubmed/35137537 http://dx.doi.org/10.1002/ehf2.13790

Ejemplares similares

Beta‐Blocker Use Is Associated With Prevention of Left Ventricular Remodeling in Recovered Dilated Cardiomyopathy
por: Enzan, Nobuyuki, et al.
Publicado: (2021)

Sex Differences in Time-Dependent Changes in B-Type Natriuretic Peptide in Hypertrophic Cardiomyopathy
por: Enzan, Nobuyuki, et al.
Publicado: (2021)

Clinical Characteristics and Contemporary Management of Patients With Cardiomyopathies in Japan　― Report From a National Registry of Clinical Personal Records ―
por: Enzan, Nobuyuki, et al.
Publicado: (2021)

Electrocardiographic Left Ventricular Hypertrophy Is Independently Associated With Better Long-Term Outcomes in Dilated Cardiomyopathy Patients
por: Matsushima, Shouji, et al.
Publicado: (2019)

Machine learning‐based model for predicting 1 year mortality of hospitalized patients with heart failure
por: Tohyama, Takeshi, et al.
Publicado: (2021)

Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction
por: Enzan, Nobuyuki, et al.
Publicado: (2020)

Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure With Preserved Ejection Fraction and Diabetes
por: Enzan, Nobuyuki, et al.
Publicado: (2023)

The appropriate dose of angiotensin‐converting‐enzyme inhibitors or angiotensin receptor blockers in patients with dilated cardiomyopathy. The higher, the better?
por: Ishida, Junichi, et al.
Publicado: (2015)

The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy
por: Liu, Tao, et al.
Publicado: (2023)

Regression of Electrocardiographic Left Ventricular Hypertrophy and Strain Pattern Using Pharmacotherapy in a Patient With Dilated Cardiomyopathy
por: Hashimoto, Toru, et al.
Publicado: (2020)

Long-Term Outcomes of Heart Failure Patients With Preserved, Mildly Reduced, and Reduced Ejection Fraction
por: Nagata, Takuya, et al.
Publicado: (2023)

Prediction of left ventricular reverse remodeling after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy
por: Matsumura, Yoshihisa, et al.
Publicado: (2015)

Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: Anti-arrhythmic Drug for Arrhythmogenic Right Ventricular Cardiomyopathy
por: Tu, Bin, et al.
Publicado: (2021)

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Propensity-Matched Study of Early Cardiac Rehabilitation in Patients With Acute Decompensated Heart Failure
por: Enzan, Nobuyuki, et al.
Publicado: (2023)

Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Gersh, Felice L.
Publicado: (2020)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Moretti, Myla E., et al.
Publicado: (2012)

Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
por: Ajmal, Adnan, et al.
Publicado: (2013)

Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide
por: Mamdani, Muhammad, et al.
Publicado: (2019)

Effects of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19
por: Li, Xiao-Long, et al.
Publicado: (2021)

Left Ventricular Noncompaction with Multiple Thrombi in Apical Aneurysm
por: Yakabe, Daisuke, et al.
Publicado: (2019)

In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Pneumonia Risk and Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Liu, Chia-Lin, et al.
Publicado: (2013)

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
por: Lee, Hyun Woo, et al.
Publicado: (2021)

Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
por: Holloway-Kew, Kara L., et al.
Publicado: (2022)

Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
por: Farid fahmy, Sarah, et al.
Publicado: (2023)

Impact of Angiotensin I Converting Enzyme Insertion/Deletion Polymorphisms on Dilated Cardiomyopathy and Hypertrophic Cardiomyopathy Risk
por: Yang, Jianmin, et al.
Publicado: (2013)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)

Premorbid Use of Beta-Blockers or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients with Acute Ischemic Stroke
por: Zeng, Yuanyuan, et al.
Publicado: (2023)

Blockade of L-type Ca(2+) channel attenuates doxorubicin-induced cardiomyopathy via suppression of CaMKII-NF-κB pathway
por: Ikeda, Soichiro, et al.
Publicado: (2019)

Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies
por: Kriszta, Gábor, et al.
Publicado: (2021)

Aliskiren – an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension
por: Zaporowska-Stachowiak, Iwona, et al.
Publicado: (2013)

Cognitive enhancing effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on learning and memory
por: Nade, V. S., et al.
Publicado: (2015)

Is angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy protective against prostate cancer?
por: Mao, Yeqing, et al.
Publicado: (2016)

Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
por: Wong, Martin C.S., et al.
Publicado: (2020)

The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients
por: Harky, Amer, et al.
Publicado: (2021)

Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker
por: Jun, Hye-Ran, et al.
Publicado: (2021)

Differential Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on COVID-19
por: Su, Lianjiu, et al.
Publicado: (2021)

Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
por: Zhang, Chao, et al.
Publicado: (2021)

Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis
por: Choi, Jin Sun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q0688mjmspgac91m8u6uuoqrpp